No Data
No Data
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a ne
Buy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical Pipeline
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Oric Pharmaceuticals Price Target Cut to $14.00/Share From $15.00 by Citigroup
Oric Pharmaceuticals Price Target Cut to $14.00/Share From $15.00 by Citigroup
Oric Pharmaceuticals Is Maintained at Buy by Citigroup
Oric Pharmaceuticals Is Maintained at Buy by Citigroup
Citi: Maintains ORIC Pharmaceuticals (ORIC.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $14.00.
Citi: Maintains ORIC Pharmaceuticals (ORIC.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $14.00.